MAPT and Alzheimer disease: Furthermore, knockdown of KYAT1 also significantly impeded the protective effect of IPA (Figs. 7b,g, p = 0.036), indicating that the gut metabolite IPA may alleviate AD Tau pathologies by sensing KYAT1.